Who Supplies Domperidone to India from FRANCE

Importing finished pharmaceutical formulations containing Domperidone into India requires compliance with the Drugs and Cosmetics Act, 1940, and associated rules. The Central Drugs Standard Control Organization (CDSCO) mandates that all imported drugs possess a valid import license issued under Form 10 of the Drugs and Cosmetics Rules, 1945. Additionally, each product must be registered with CDSCO under Form 41, which serves as authorization for importation. Importers must also obtain an Importer Exporter Code (IEC) from the Directorate General of Foreign Trade (DGFT) to facilitate customs clearance. The registration process involves submitting comprehensive data on the drug's safety, efficacy, and quality, including stability studies in accordance with ICH guidelines. The timeline for obtaining these approvals can vary, but it typically ranges from several months to over a year, depending on the complexity of the product and the efficiency of the regulatory bodies. For formulations under HS Code 30049039, specific requirements include detailed product dossiers, manufacturing licenses from the country of origin, and a No Objection Certificate (NOC) from the manufacturer authorizing the import. It's crucial to ensure that all documentation is current and complies with Indian regulations to avoid delays or rejections.

Imported pharmaceutical formulations containing Domperidone must undergo quality testing to ensure they meet Indian standards. CDSCO-approved laboratories conduct batch-wise testing, which includes verifying the Certificate of Analysis (CoA) provided by the manufacturer. Stability data, particularly in ICH Zone IV conditions, is essential to demonstrate the product's shelf-life and efficacy under Indian climatic conditions. The Indian Pharmacopoeia sets the standards for quality, purity, and strength. Upon arrival, customs drug inspectors perform port inspections to assess compliance with these standards. If a batch fails to meet the required criteria, it may be rejected, leading to potential financial losses and reputational damage for the importer. Therefore, ensuring that all imported batches comply with Indian quality standards is imperative for market acceptance and patient safety.

Between 2024 and 2026, the CDSCO has implemented several regulatory updates affecting pharmaceutical imports. Notably, the introduction of the Production Linked Incentive (PLI) scheme has incentivized domestic manufacturing, potentially impacting the volume of finished formulation imports. Additionally, the CDSCO has streamlined procedures for the transfer of drugs manufactured in Special Economic Zones (SEZs) to the Domestic Tariff Area (DTA), emphasizing compliance with quality, safety, and efficacy standards. These changes aim to bolster domestic production capabilities and reduce dependency on imports, aligning with India's self-reliance initiatives. Importers should stay informed about these policy shifts to navigate the evolving regulatory landscape effectively.

India imports finished Domperidone formulations to meet the demand for specific dosage forms and branded products not available domestically. The domestic market for Domperidone is substantial, with a total export value of $29.6 million across 493 exporters to 115 countries. However, certain specialized formulations, such as specific tablet strengths or combination products, may not be manufactured locally, necessitating imports. The reliance on imports is also influenced by factors like patent protections and the availability of advanced manufacturing technologies in the exporting countries. Understanding these dynamics is crucial for stakeholders aiming to navigate the Indian pharmaceutical market effectively.

The import of finished pharmaceutical formulations containing Domperidone (HS Code 30049039) into India is subject to a Basic Customs Duty (BCD) of 10%. Additionally, a Social Welfare Surcharge (SWS) of 10% on the BCD is applicable. The Integrated Goods and Services Tax (IGST) is also levied, with the rate varying based on the specific product classification. There are no exemptions or preferential rates for imports from France under the Most Favored Nation (MFN) status. Importers should account for these duties and taxes when calculating the total landed cost of imported goods.

India sources finished Domperidone formulations from France due to the country's strong pharmaceutical manufacturing capabilities, adherence to international quality standards, and the availability of specialized formulations. French manufacturers often offer patented or branded products that are not produced domestically, providing a competitive edge in the Indian market. While other countries like China, Germany, and the United States also export pharmaceutical products to India, France's reputation for quality and innovation makes it a preferred source for certain formulations. The French pharmaceutical sector's commitment to research and development further enhances its position in the global market.

India imports finished Domperidone formulations from France to access specialized dosage forms and branded products not available domestically. French manufacturers often provide patented formulations and advanced technologies that enhance the therapeutic efficacy of Domperidone. These imports cater to specific patient needs and market segments, ensuring a diverse and comprehensive product offering in the Indian market.

When compared to other sourcing countries like China, Germany, and the United States, France offers distinct advantages in terms of product quality, regulatory compliance, and innovation. French pharmaceutical products are renowned for their adherence to stringent quality standards and their ability to meet specific market demands. While other countries may offer competitive pricing, France's reputation for quality and reliability makes it a preferred choice for certain pharmaceutical imports.

Importing finished pharmaceutical formulations from France involves certain risks